Skip to main content
REGN
NASDAQ Life Sciences

雷根诺与Telix合作成立放射药物合作伙伴关系，潜在价值超过21亿美元

feedReported by Dow Jones Newswires
Sentiment info
Positive
Importance info
8
Price
$749.36
Mkt Cap
$79.158B
52W Low
$476.487
52W High
$821.11
Market data snapshot near publication time

summarizeSummary

雷根诺制药公司宣布与澳大利亚的Telix制药公司成立战略放射药物合作伙伴关系。合作内容包括共同开发和共同商业化治疗方法，成本和利润均分。Telix将因最初的四个项目获得4000万美元的预付款，协议的潜在价值可能超过21亿美元，包括开发和商业里程碑付款，以及低位数的特许权使用费。该合作伙伴关系扩大了雷根诺在放射药物领域的产品线，利用Telix的开发和制造能力与雷根诺的抗体发现平台。这种合作伙伴关系是雷根诺的一项重要战略举措，有可能推动未来的增长并多元化雷根诺的治疗产品。

在该公告发布时，REGN的交易价格为$749.36，交易所为NASDAQ，所属行业为Life Sciences，市值约为$791.6亿。 52周交易区间为$476.49至$821.11。 这则新闻被评估为积极市场情绪，重要性评分为8/10。 来源：Dow Jones Newswires。

show_chartPrice Chart

Share this article

Copied!

feed REGN - Latest Insights

REGN
Apr 29, 2026, 6:54 AM EDT
Filing Type: 10-Q
Importance Score:
8
Regeneron Reports Mixed Q1 Results, Authorizes $3B Buyback, Details Government Pricing Deals & Key Legal Updates
Sentiment: Neutral
View Wiseek Article
REGN
Apr 29, 2026, 6:50 AM EDT
Filing Type: 8-K
Importance Score:
8
Regeneron Reports Strong Q1 Results, Authorizes New $3.0 Billion Share Repurchase, and Secures Strategic Government Pricing Agreement
Sentiment: Positive
View Wiseek Article
REGN
Apr 29, 2026, 6:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Regeneron Posts 19% Revenue Growth in Q1, Non-GAAP EPS Up 15% Amidst GAAP Decline
Sentiment: Positive
View Wiseek Article
REGN
Apr 24, 2026, 12:25 AM EDT
Source: dpa-AFX
Importance Score:
8
Regeneron's Otarmeni Gene Therapy Approved by FDA for Genetic Hearing Loss
Sentiment: Positive
View Wiseek Article
REGN
Apr 23, 2026, 12:42 PM EDT
Source: Reuters
Importance Score:
8
FDA Approves Regeneron's Gene Therapy for Inherited Deafness
Sentiment: Positive
View Wiseek Article
REGN
Apr 23, 2026, 1:30 AM EDT
Source: Reuters
Importance Score:
7
Dupixent Sales Soar 30.8%, Beating Estimates in Sanofi's Q1 Report
Sentiment: Positive
View Wiseek Article
REGN
Apr 22, 2026, 5:30 PM EDT
Source: GlobeNewswire
Importance Score:
8
Dupixent Gains U.S. Approval for Young Children with Chronic Spontaneous Urticaria
Sentiment: Positive
View Wiseek Article
REGN
Apr 21, 2026, 10:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Regeneron's Cemdisiran Phase 3 Data Published, Regulatory Filing Submitted for gMG
Sentiment: Positive
View Wiseek Article
REGN
Apr 13, 2026, 1:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Dupixent Secures EU Approval for Young Children with Chronic Urticaria, Expanding Key Market
Sentiment: Positive
View Wiseek Article
REGN
Apr 12, 2026, 7:08 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Regeneron Forms Radiopharma Partnership with Telix, Potentially Worth Over $2.1 Billion
Sentiment: Positive
View Wiseek Article